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parison with FD treatment. Late start of treatment (FD or TD) 
did not show a renoprotective effect.  Conclusions: Titration 
of a V2RA aimed to maintain aquaresis at a high level showed 
a better renoprotective effect compared to FD administra-
tion. However, this treatment regimen was poorly tolerated 
and did not overcome treatment unresponsiveness when 
started later in the disease.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Autosomal dominant polycystic kidney disease 
 (ADPKD) is a hereditary kidney disease with an estimat-
ed point prevalence of clinically diagnosed cases of 3 per 
10,000 subjects in the general population  [1] . ADPKD is 
characterized by cyst formation in both kidneys and renal 
function loss, leading to end-stage kidney failure in most 
affected patients.
 The pathogenesis of ADPKD is complex and not fully 
understood. However, it is generally acknowledged that 
elevated intracellular levels of adenosine 3 ′ :5 ′ -cyclic mo-
nophosphate (cAMP), formed by adenylyl cyclase, are 
part of the pathway leading to renal tubular cell prolifera-
tion and increased chloride-driven fluid secretion by 
these cells. Both processes contribute to cyst formation 
and growth  [2] . Studies using in vitro ADPKD cells dem-
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 Abstract 
 Background: In autosomal dominant polycystic kidney dis-
ease, renoprotective treatment with a vasopressin V2 recep-
tor antagonist (V2RA) is given in a fixed dose (FD). Disease 
progression and drug habituation could diminish treatment 
efficacy. We investigated whether the renoprotective effect 
of the V2RA can be improved by dose titration of the V2RA 
aiming to maintain aquaresis at a high level.  Methods: The 
V2RA OPC-31260 was administered to  Pkd1 -deletion mice in 
an FD (0.1%) or in a titrated dose (TD, up to 0.8% when drink-
ing volume dropped). Total kidney weight (TKW) and cyst 
ratio were investigated and compared to non-treated  Pkd1 -
deletion mice. Treatment was started early or late (21 or 42 
days postnatal).  Results: Water intake was significantly high-
er throughout the experiment in the TD compared to the FD 
group. FD treatment that was initiated early reduced TKW 
and cyst ratio but lost its renoprotective effect later during 
the experiment. In contrast, TD treatment was able to main-
tain the renoprotective effect. TD treatment, however, was 
also associated with a higher early termination rate in com-
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onstrated that administration of cAMP, or an adenyl cy-
clase agonist like vasopressin, leads to cell proliferation 
 [3] and fluid accumulation  [4] . Moreover, blocking the 
vasopressin V2 receptor in animal models attenuated dis-
ease progression  [5–10] . In line with these reports, a re-
cent multicenter randomized controlled trial showed that 
a vasopressin V2 receptor antagonist (V2RA) slowed the 
increase in total kidney volume and the decline in kidney 
function over a 3-year period in patients with relatively 
early stage ADPKD  [11] . The most frequently reported 
adverse events were polyuria and polydipsia. These ad-
verse events can be expected, as water reabsorption in the 
collecting duct, enabled by aquaporine-2 water channels, 
relies on the stimulation of the V2 receptor  [12] . The ben-
eficial renoprotective effect of V2RA treatment is there-
fore accompanied by a strong aquaretic response. In ad-
dition, potential hepatotoxicity was observed in individ-
ual cases.
 Optimum dosage of the drug is yet debatable. As of 
now, all studies investigated a fixed-dose (FD) treatment 
regimen. However, it has been suggested that disease se-
verity and treatment duration may interfere with treat-
ment efficacy, as indicated by a decline in aquaretic re-
sponse to V2RAs in later stage disease and during pro-
longed treatment  [8, 13, 14] . We hypothesized therefore 
that the renoprotective effect of the V2RA can be opti-
mized when the dose of the V2RA is increased during 
treatment, aiming to maintain aquaresis at a high level, to 
overcome drug habituation. We studied this hypothesis 
in a  Pkd1 -deletion mouse model with high face validity to 
the human situation, in early- and later-stage disease.
 Material and Methods 
 Experimental Animals 
 For this experiment, the tamoxifen-inducible kidney epitheli-
um-specific  Pkd1 -deletion mouse was used. Upon administration 
of tamoxifen, a genomic fragment containing exons 2–11 of the 
 Pkd1 gene is specifically deleted in renal epithelial cells and cysts 
are formed. This inducible  Pkd1 -deletion mouse model (tam-
KspCad-CreER T2 ; Pkd1 lox2–11/lox2–11 ) has been described earlier  [8, 
15] . We administered tamoxifen per gavage (0.22 mg dissolved in 
ethanol in 0.30 μl sunflower oil; Sigma-Aldrich, St. Louis, Mo., 
USA) for 3 consecutive days starting at postnatal day 12. Gene de-
letion was induced early in life to induce cyst formation in collect-
ing ducts and distal tubules and to develop a more rapid progres-
sive form of ADPKD. All mice were genotyped using a polymerase 
chain reaction method and had a confirmed homozygote  Pkd1 -
deletion. Male and female animals were stratified over the study 
groups and analyzed together as no difference in rate of disease 
progression has been noted in this model across sex.
 Experimental Design 
 Figure 1 displays an overview of the experimental design. At 
3 weeks of age, tamoxifen treated mice were divided into a no-
treatment (NT) group and 4 treatment groups: FD early start of 
treatment (FDE), titrated dose (TD) early start of treatment (TDE), 
FD late start of treatment (FDL), and TD late start of treatment 
(TDL;  table 1 ). Mice not treated with tamoxifen served as a healthy 
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 Fig. 1. Experimental design. 
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control group (HC). This time point serves as baseline, that is, as 
week 0 of the experiment.
 The V2RA OPC-31260 (Mozavaptan) was added to ground ro-
dent chow (AB Diets BV, RMH-B starch, 2103) at a starting dose 
of 0.1% and was given to all mice on treatment. This 0.1% dose is 
equivalent to the dose used in literature  [6, 9] and has been used in 
this particular  Pkd1 mouse model by our research group before  [8] .
 According to welfare regulations, it was not possible to house 
mice individually at the start of the study because of their small size 
at 3 weeks of age. Therefore, mice were housed with an average of 
3 mice per cage. Animals, water and food where weighed 2 times a 
week. Water intake of the cage was divided by the number of mice 
per cage, the number of days between 2 consecutive measurements 
and weight in order to obtain an average water intake per animal 
per day. Water intake was adjusted for body weight because mice 
grew to maturity during the experiment and this is accompanied 
by an increase in water intake.
 When water intake of mice in the TD treatment groups de-
creased with more than 10% compared to the average water intake 
during the first 2 consecutive measurements in the first week, the 
dose of the V2RA was increased to 0.2%. When again drinking 
volume dropped with 10% compared to the first 2 consecutive 
measurements in the first week, the dose was again increased. The 
dose scheme of the V2RA was: 0.1, 0.2, 0.4, 0.6, and 0.8%, respec-
tively ( fig. 1 ). Mice in the FD treatment groups continued treat-
ment with 0.1% V2RA. Treatment was started either at 21 days 
postnatal (day 0 of the experiment, ‘early’) or at 42 days postnatal 
(week 3 of the experiment, ‘late’). At day 0, weeks 3 and 6 of the 
experiment mice were sacrificed. Early termination (ET) criteria 
were weight loss of >20% or change in skin, hair or locomotion. 
When mice were sacrificed >1 week before the planned sacrifice, 
they were counted as ET and excluded from all analyses ( table 1 ).
 All experiments were approved by the local animal experiment 
committee of the University Medical Center Groningen and by the 
Committee Biotechnology in Animals of the Dutch Ministry of 
Agriculture.
 Data Collection 
 Twenty-four-hour urine output was obtained for individual 
mice by placing them in metabolic cages before mice were sacri-
ficed at week 3 or 6 of the experiment. Subsequently, the animals 
were weighed and anesthetized with isoflurane gas (0.5% isoflu-
rane with a flow of 0.6 l/min). Blood was obtained by cardiac punc-
ture for determination of plasma electrolytes, creatinine, urea, as-
partate transaminase (AST), alanine transaminase (ALT) and bili-
rubin. Both kidneys were removed and kidney weight was 
measured on a precision scale. Half of the right kidney was placed 
into formaldehyde and tissues were embedded in paraffin for his-
tomorphometry and immunohistochemistry.
 Plasma and Urine Analysis 
 Sodium, potassium, urea and creatinine were measured in plas-
ma and urine, using Kodak Ektachem dry chemistry (Modular P, 
Roche, Mannheim, Germany). Urine osmolality was calculated as 
2 × (urine sodium concentration + urine potassium concentra-
tion) + urine urea concentration  [16] . Plasma osmolality was cal-
culated using the formula: 1.9  * (plasma sodium concentration + 
plasma potassium concentration) + plasma glucose concentra-
tion + plasma urea concentration  * 0.5 + 5  [17] .
 Immunohistochemistry and Histomorphometric Analysis 
 Transverse tissue sections (4 μm), including cortex, medulla 
and papilla, were stained with periodic acid Schiff and hematoxy-
lin-eosin to measure cyst ratio  [8] and with sirius red collagen stain 
to measure the extent of fibrosis  [18] . The total cyst and fibrosis 
areas were quantified using Aperio Image Scope software version 
9.1.772.1570 (Aperio Technologies Inc., Vista, Calif., USA). Kid-
neys were outlined manually, pyelum not included. Cyst ratio was 
calculated by dividing total cysts area by total tissue area and mul-
tiplied by 100% to obtain a cyst ratio, expressed as percentage. The 
total intensity of fibrosis staining was divided by the total intensity 
on the slide (both positive and negative) and multiplied by 100% 
to obtain a percentage of fibrosis. The investigator performing 
these measurements was blinded to disease and treatment status. 
To calculate the medulla/cortex cyst ratio, 5 squares in both me-
dulla and cortex were drawn and the average cyst ratio was deter-
mined for both areas separately to calculate the medulla/cortex 
ratio.
 Statistical Analyses 
 Differences between 2 groups were tested using a non-para-
metric independent sample test (Mann–Whitney) and differences 
between all groups were tested using a Kruskal–Wallis test or Pear-
son’s chi-square test. Analyses were performed using the statistical 
Table 1.  Number of Pkd1-deletion and healthy control mice randomized across the various experimental groups 
and at the time points of sacrifice. Body weight and gender were not different between the experimental groups at 
randomization. However, the early termination rate was higher in the titrated dose early start of treatment group
Groups Total, n Week 0, n Week 3  Week 6 ET: total, n (%)
n ET n ET
HC 17 6 4 0 7 0 0/17 (0)
NT 37 10 11 0 16 2 2/37 (5)
FDE 21 11 0 10 0 0/21 (0)
TDE 25 9 0 16 6 6/25 (24)
FDL 12 12 1 1/12 (8)
TDL 11 11 1 1/11 (9)
Total 123 16 35 0 72 10 10/123 (8) 
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package IBM SPSS statistics version 20.0 (International Business 
Machines Corp., Chicago, Ill., USA). A 2-sided p < 0.05 was con-
sidered to indicate statistical significance.
 Results 
 At the start of the experiment,  Pkd1 -deletion mice 
were randomized over the following experimental groups: 
NT, FDE, FDL, TDE, and TDL.  Table 1 shows the number 
of mice randomized to the various treatment groups and 
mice that needed to be sacrificed because they met the ET 
criterion of weight loss >20%.  Figure 1 gives an overview 
of the experimental design. Body weight and gender were 
not different between the experimental groups at ran-
domization (p = 0.39 and p = 0.79, respectively). More-
over, at start of the study body weight and total kidney 
weight (TKW), of mice that were sacrificed at week 0, 
were similar between HC male and female mice (p = 0.17 
and p = 0.63, respectively) and  Pkd1 -deletion male and 
female mice (p = 0.51 and p = 0.53, respectively).
 Non-Treated ADPKD 
 Pkd1 -deletion mice developed cysts and kidney func-
tion deterioration during the experiment. Study param-
eters indicative for renal damage (TKW, cyst ratio, fibro-
sis ratio, plasma creatinine and plasma urea) were all sig-
nificantly increased in  Pkd1 -deletion animals compared 
to HCs at weeks 3 and 6 of the experiment ( fig. 4 ; online 
suppl. tables 1 and 2; for all online suppl. material, see 
www.karger.com/doi/10.1159/000448693).
 Water intake was significantly higher in non-treated 
 Pkd1 -deletion mice compared to HCs throughout the 
whole experiment, starting already at day 0 (p < 0.001; 
 fig. 2 ). Together with a significant lower 24-hour urine 
osmolality and an increased plasma osmolality at weeks 3 
and 6 of the experiment in these non-treated  Pkd1 -dele-
tion mice group ( fig. 3 ), this suggests an early urine con-
centrating defect. Although bodyweight was similar at 
randomization,  Pkd1 -deletion mice showed lower growth 
rates compared to HC mice with a significantly lower 
bodyweight at week 3 (p = 0.001) and 6 (p = 0.01), while 
food intake (adjusted for body weight) was similar both 
at 3 weeks (p = 1.00) and 6 weeks (p = 0.84) of the exper-
iment.
 FDE Treatment 
 Water intake increased after the initiation of V2RA 
treatment. However, the aquaretic response in the FD 
treatment group waned during the course of treatment. 
At week 3, water intake was still higher in treated 
























































































 Fig. 2. Mean water intake ( a ) and body weight ( b ) of mice in the various treatment groups during the experiment. 
The arrow indicates the time-point at which dose titration of the V2RA was started. 
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week 6 this difference did not reach significance any-
more (p = 0.09;  fig. 2 ). In line, the increase in 24-hour 
urine volume during treatment lost statistical signifi-
cance ( fig. 3 ). The osmolality of 24-hour urine, how-
ever, remained significantly lower at weeks 3 (p = 0.005) 
and 6 (p = 0.004) of the experiment ( fig. 3 ). Body weight 
was higher in the FD treatment group during the last 
weeks of the experiment compared to non-treated mice 
( fig. 2 ).
 TKW was significantly lower in the FD treatment 
group compared to non-treated  Pkd1 -deletion mice at 
week 3 of the experiment (p = 0.02). However, at week 6, 
this difference also lost statistical significance (p = 0.26; 
 fig. 4 ). Body weight in the FD treatment group compared 
to non-treated  Pkd1 -deletion mice was similar at week 3 
(p = 0.16) and borderline significantly higher at week 6 of 
the experiment (p = 0.05). Food intake (adjusted for body 
weight) was equal between these groups at week 3 (p = 
0.56) but lower in the FD treatment group compared to 
non-treated  Pkd1- deletion mice (p = 0.04) at week 6 of the 
experiment. Cyst ratio, fibrosis ratio and plasma creati-
nine did not differ between the 2 groups at weeks 3 and 6 
(online suppl. tables 1 and 2).
 TDE Treatment 
 At start of the experiment (day 0), the dose of the 
V2RA in the titrated and FD treatment groups was the 
same and both groups showed a similar increase in water 
intake. After 1 week, water intake decreased by more than 
>10% in both treatment groups. Per protocol, dose titra-
tion of the V2RA was started in the TDE treatment group, 
resulting in a higher V2RA dose (average mean dose of 
0.75% V2RA at week 6 of the experiment, average overall 
dose of 0.38%, p < 0.001) and significantly higher water 
intake (p  = 0.04) and lower 24-hour urine osmolality 
(week 3: p = 0.004, week 6: p = 0.04) compared to the FD 
treatment group that still received 0.1% V2RA ( fig. 2 ,  3 ). 
Body weight was lower in the TD treatment group com-
pared to the FD treatment group (p = 0.002) and non-
treated  Pkd1 -deletion animals (p = 0.04) at week 6 of the 
experiment ( fig.  2 ). Food intake (adjusted for body 
weight) at this time point was similar in comparison to 
the FD treatment group (p = 0.81) but lower in compari-
son to non-treated  Pkd1 -deletion mice (p = 0.01).
 In contrast to mice in the FD treatment group, the 
renoprotective effect of the V2RA was seen throughout 







































































































 Fig. 3. Twenty-four-hour urine osmolality ( a ) and 24-hour urine 
volume ( b ) at weeks 3 and 6 of the experiment. X-axis displays, 
besides the various treatment groups, the mean dose of the V2RA 
administration during 24-hour urine collection. Data are dis-
played as mean and SD.  * p < 0.05 compared to the HC mice;  # p < 
0.05 compared to the non-treated  Pkd1 -deletion mice. 
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TKW at week 3 (p = 0.004) and week 6 (p < 0.001) and a 
lower cyst ratio at week 6 in comparison to non-treated 
 Pkd1 -deletion mice (p = 0.04;  fig. 4 ). When comparing 
the fixed and TD treatment groups, TKW was similar at 
week 3. However, at week 6 of the experiment TKW was 
significantly lower in the TD treatment group compared 
to the FD treatment group (p = 0.004;  fig. 4 ). A similar 
trend was observed for cyst ratio, although the difference 
did not reach formal statistical significance (p = 0.17). Fi-
brosis ratio, plasma creatinine and plasma osmolality 
were similar (online suppl. tables 1 and 2).
 When investigating the medulla/cortex cyst ratio in 
the non-treated  Pkd1 -deletion mice, in our model, cysts 
were first mainly located in the medulla. When disease 
progressed, the medulla/cortex ratio decreased signifi-
cantly, indicating the growth of cortical cysts. At week 6 
of the experiment, the medulla/cortex cyst ratio was high-
er in the TD treated group compared to that in the non-
treatment group (p = 0.06). This was not the case for the 
FD treatment group. Furthermore, in the FD treatment 
group, the medulla/cortex cyst ratio declined significant-
ly when comparing weeks 3 and 6 (p < 0.001), while in the 
TD treatment group, the medulla/cortex cyst ratio re-
mained more stable ( fig. 5 ).
 The TD treatment regimen was poorly tolerated during 
the second half of the experiment. When the V2RA dose 
was increased, the weight of mice decreased before stabi-
lizing after a few days, resulting in a high number of ETs 
in the second half of the experiment (6 out of 16 mice in 
the TD treatment group versus 0 out of 10 mice in the FD 
treatment group;  table 1 ). The mean TKW of early termi-
nated mice in the TD treatment group was 0.56 g. In com-
parison, the mean TKW of mice in the titrated treatment 
group and non-treated  Pkd1 -deletion mice at week 6 of 
the experiment was 0.70 and 1.24 g, respectively.
 As potential hepatotoxicity was observed in human 
studies involving V2RA treatment, several parameters re-
flecting liver function were investigated. The TD treat-
ment regimen did not cause an elevation in AST, ALT or 
bilirubin compared with non-treated mice (178 vs. 238 
U/l, p = 0.92; 83 vs. 83 U/l, p = 0.44; 6 vs. 5 μmol/l, p = 
0.92, respectively) or FD-treated mice (178 vs. 217 U/l, 
p = 0.89; 83 vs. 57 U/l, p = 0.27; 6 vs. 5 μmol/l, p = 0.40, 
respectively). Furthermore, liver histology of mice treated 
with the TD of the V2RA was similar in comparison with 
non-treated and FD-treated mice.
 Early versus Late Start of Treatment 
 When treatment with 0.1% V2RA treatment started 
late (FDL), that is, at week 3 of the experiment, water in-
take increased compared to non-treated  Pkd1 -deletion 
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 Fig. 4. TKW ( a ) and cyst ratio ( b ) at weeks 3 and 6 of the experiment. Data are displayed as mean and SD.  * p < 
0.05 compared to the HC mice;  # p < 0.05 compared to the non-treated  Pkd1 -deletion mice. 
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intake at the start of treatment in the early treatment 
groups (p = 0.004). The TDL underwent a similar up-ti-
tration schedule compared with the TDE group during 
their first 3 weeks of treatment. Nevertheless, the average 
water intake in this group was significantly lower (p  = 
0.01) than that of mice in the early start of titration treat-
ment group in their first weeks of the experiment.
 Starting treatment later in the disease course, using a 
fixed or TD treatment regimen, did not have an effect on 
the various parameters for renal damage (TKW, cyst ra-
tio, fibrosis ratio, and plasma creatinine and osmolality) 
in comparison with non-treated mice (online suppl. ta-
ble 2 and fig. 4).
 Discussion 
 In this experiment, we studied the effects of titration 
of a V2RA in an ADPKD mouse model. By aiming to 
maintain water intake at a high level, we tried to over-
come potential habituation to the V2RA and improve the 
renoprotective efficacy of this drug in the early and later 
stage of the disease. During the experiment, the aquaretic 
response to dose titration was indisputable. Water intake 
was significantly higher throughout the experiment in 
mice that received the TD-treatment regimen compared 
to the FD-treatment regimen. This was associated with a 
renoprotective effect, also later in the disease. In our 
model, cyst formation starts predominantly in the distal 
tubular segments, whereas later on also, cysts arise in the 
cortex. In comparison to FD treatment, TD treatment 
had an inhibitory effect on cyst formation in the cortex as 
well, indicating the ongoing benefit of titration of the 
V2RA. Unfortunately, the renoprotective effect of V2RA 
titration was obtained at the cost of a higher ET rate in the 
titrated treatment group. Moreover, the titrated treat-
ment regimen could not overcome the unresponsiveness 
of the V2RA when started in a later stage of the disease.
 Previously, we hypothesized that when ADPKD pro-
gresses more, vasopressin is released from the pituitary 
gland, as a response to the impaired urine concentrating 
capacity that is observed in more severe form of the dis-
ease  [19] . Indeed, we have found that copeptin, a surro-
gate marker for vasopressin, is positively associated with 
disease severity  [20, 21] , which fits this hypothesis. Fur-
thermore, during V2RA treatment, vasopressin levels in-
crease  [8, 22] and it has been suggested that the expres-
sion of the vasopressin V2 receptor is downregulated via 
the stimulation of the vasopressin V1 receptor  [23, 24] . 
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 Fig. 5. Tissue morphology at week 6 of the experiment ( a ) and the medulla/cortex cyst ratio at weeks 0, 3 and 6 
of the experiment ( b ). Data are displayed as mean and SD. 
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especially when treated with a V2RA, more AVP per re-
ceptor will be present and thus that a higher dose of the 
V2RA may be needed to result in effective receptor block-
ade. Indeed, our experiment shows that dose titration of 
the V2RA during disease progression results in a stronger 
aquaretic response and improved renoprotection when 
compared to an FD-treatment regimen. However, no ef-
fect of V2RA treatment was seen when initiated later in 
the disease. Dose titration (from 0.1 to 0.4%) was not able 
to overcome this decreased efficacy for the cystic pheno-
type. A possible explanation is that during disease pro-
gression other cystogenic mechanisms not involving 
cAMP become more important, for instance, pathways 
involving growth factors or macrophages  [2] . Loss of 
functioning nephrons may also explain the lack of effi-
cacy when treatment is initiated later in the disease. In-
volvement of the vasopressin V2 receptor itself in treat-
ment unresponsiveness could explain the less profound 
aquaretic response as well. Mechanisms that can be taken 
into consideration are for instance loss of vasopressin V2 
receptors when cysts disconnect from the tubular system 
or vasopressin V2 receptor dedifferentiation. In line with 
this theory are results from our previous animal experi-
ment that showed a decrease in V2-receptor mRNA ex-
pression over time in non-treated ADPKD animals  [8] .
 The reason for the high dropout rate seen in mice on 
the high V2RA dose is not entirely clear from the present 
experiment. In contrast to what is found in humans  [11] , 
we did not find elevated liver enzymes indicative for hep-
atotoxicity of the V2RA in our mice. Histology of the liv-
er was not different between the non-treated and treated 
 Pkd1 -deletion mice either. This is in line with experi-
ments in mice reporting no toxicity after administration 
of a single 1,000 mg/kg dose, which is equivalent to our 
0.8%  [25] . In the present experiment we did, however, 
observe a decrease in body weight, especially in the mice 
that received the titrated treatment regimen. Kidney 
weight of these early terminated animals was significant-
ly lower compared to the non-treated controls, indicating 
that disease progression per se is not a likely cause of this 
weight loss. We hypothesize that this weight loss is caused 
by their effort to drink up to 1.5 times their bodyweight 
per day, which may have caused inadequate food intake. 
Almost a quarter of the animals had to be sacrificed be-
cause of pre-specified ET criterion regarding weight loss. 
It is not likely that this is related to the fact that mice had 
polycystic kidney disease because in healthy rats and 
dogs, similar mortality rates have been described on a dai-
ly 1,000 mg/kg dose, likewise without a clear cause of 
death  [25] .
 Translating experimental data into clinical practice is 
difficult and should be done with caution. Our experiment 
shows, however, that a better therapeutic response can be 
achieved when higher doses of the V2RA are used. This 
suggests that dose titration of a V2RA in clinical practice, 
when disease progresses and the aquaretic response to the 
V2RA decreases, may be beneficial. However, this reno-
protective effect was counteracted by significant side ef-
fects. Moreover, this rigorous treatment regimen did not 
overcome therapeutic unresponsiveness when started in a 
later stage of the disease. Animal  experiments performed 
by other research groups did not describe a decrease in 
responsiveness during long-term treatment as we ob-
served in our model  [6, 7, 9, 10] . In addition, results of a 
post-hoc analysis of the TEMPO 3: 4 trial showed that a 
V2RA was similarly effective in reducing the rate of total 
kidney volume increase and eGFR decline in ADPKD pa-
tients with CKD stages 1 to 3a  [26] . Many factors, includ-
ing the experimental model, dosage of the V2RA and dis-
ease severity, may explain the differences between these 
studies. Regardless of the variance of the present results 
and previous data, clinical studies are needed to verify the 
efficacy and safety of long-term V2RA treatment, espe-
cially in ADPKD patients with a more advanced form of 
the disease (CKD stages 3b and 4).
 To enhance therapeutic efficacy, combination therapy 
could be of more use. Theoretically, somatostatin ana-
logues induce a similar effect on intracellular cAMP pro-
duction as V2RAs because both drug classes inhibit ade-
nylyl cyclase, the enzyme that converts adenosine tri-
phosphate into cAMP  [27] . Interestingly, Hopp et al.  [28] 
recently showed in a  Pkd1 experimental model that com-
bination treatment with a somatostatin analogue and a 
V2RA indeed led to lower cAMP levels and less cyst pro-
gression when compared to monotherapy with either of 
the drugs. A combination of these drugs may allow the 
use of lower doses of each single drug, thereby limiting 
adverse events, while optimizing renoprotective efficacy. 
These results are promising and seem to be a more logical 
direction for future research than applying higher doses 
monotherapy.
 We acknowledge that this experiment has limita-
tions. First, the rapidly progressive model used in this 
experiment does not exactly resemble the clinical situa-
tion where ADPKD is often a more slowly progressive 
disease. However, this model allowed us to investigate 
the effect of titration as well as start of treatment in the 
later stages of the disease. Second, it was not possible to 
house mice individually at the start of the study because 
of their small size at 3 weeks of age. We preferred early 
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start of treatment over individually housed animals. 
Therefore, mice were housed with an average of 3 mice 
per cage and titration of the V2RA treatment was based 
on the average water intake of 3 mice. Third, bodyweight 
of the mice in the TD treatment group was lower com-
pared to the other study groups. Because water intake 
remained higher in the TD treatment group compared 
to the other groups and responded to titration steps, a 
lower food intake and consequently, possibly a lower 
dose of the V2RA is not a concern. Nevertheless, recent 
studies in mice revealed that a lower food intake can also 
be protective in ADPKD  [29, 30] . Although food intake 
(adjusted for body weight) in the TD treatment group 
was similar after 6 weeks of study in comparison to the 
FD treatment group, body weight was markedly differ-
ent between these study groups at the end of our exper-
iment. We therefore cannot exclude a possible influence 
of food intake on disease progression. The strengths of 
this experiment include the unique experimental design 
that addresses a study question that has not been inves-
tigated previously, the use of a  Pkd1 -deletion model 
with high face validity to the human situation where 
ADPKD is caused by mutations in the  PKD1 gene in 
85% of cases, and the potential clinical relevance of our 
findings.
 In conclusion, titration of a V2RA aimed to maintain 
aquaresis at a high level, showed a better renoprotective 
effect compared to FD administration in this ADPKD 
mouse model. However, this TD treatment regimen was 
poorly tolerated and did not overcome treatment unre-
sponsiveness when started later in the disease stage.
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